Page 333 - Demo

331PhD portfolioFragile X syndrome: physiopathology, therapeutics, innovative therapies and drug candidates2021 0.5Academische geneesmiddelenontwikkeling, Nationaal Farmaceutisch Kenniscentrum2021 3.0Online presenteren met impact 2021 0.1Making Science Visual 2021 0.1Drug repurposing 2021 0.1CBG-collegedag 2021 0.3Stofwisselingsziekten, publieksavond 2021 0.1European Joint Programme on Rare Diseases (EJP-RD) workshops and seminars2022 0.5ERN scientific symposium N-of-1 Neurology 2022 0.1Cannabidiol for Dravet and Lennox-Gastaut syndrome 2022 0.1Solve-RD: The Treatabolome project; public symposium 2022; 2023 0.3DORP master protocols 2022 0.1ERNICA: Clinical trials 2023 0.1Epicare evidence real-world data 2023 0.1PresentationsOralThe power of 1Erasmus MC ENCORE, Rotterdam; Radboud UMC, Nijmegen; Amsterdam UMC, Amsterdam2020 0.5The power of 1Arts VG regio-overleg, virtual2020 0.5Trial designs voor behandeling van neurologische ontwikkelingsstoornissenMini-symposium Alternatieve trial designs voor behandeling van zeldzame ziekten, virtual2021 0.5The power of 1: N-of-1 studies in rare genetic neurodevelopmental disorders & Methylphenidate for ADHD in Smith-Magenis syndromeInternational Association for the Scientific Study of Intellectual and Developmental Disabilities (IASSIDD), virtual2021 1.0Het belang van (gepersonaliseerde) uitkomstmatenArts VG scholingsdag, Utrecht2021 0.5Cannabidiol for severe behavioral manifestations in RGNDsFragiele X expertisenetwerk, virtual2021 0.5Cannabidiol for severe behavioral manifestations in RGNDsVereniging Klinische Genetica Nederland, LOG-LOD, virtual2021 0.5Trial designs and outcome measures22q11 Lage Landen overleg, virtual2021 0.5Annelieke Muller sHL.indd 331 14-11-2023 09:08